Reaction

Jc Virus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,577 reports · 88 co-occurring drugs

As of the last recalculation, Jc Virus Infection appears in 1,577 FAERS reports alongside 88 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 81.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Busulfan	92	81.9	82.4
Basiliximab	61	71.2	71.5
Alemtuzumab	95	68.9	69.3
Fludarabine Phosphate	179	67.6	68.0
Bendamustine Hcl	68	60.4	60.7
Oseltamivir	35	59.3	59.6
Melphalan	93	57.3	57.5
Valganciclovir Hydrochloride Powder,	50	55.8	56.1
Mycophenilic Acid	79	52.9	53.1
Melphalan Hydrochloride	94	52.6	52.8
Thiotepa	36	50.9	51.1
Tacrolimus Ointment 0.1%	357	48.6	48.8
Tacrolimus Extended-Release Capsules	357	48.5	48.6
Mycophenolate Mofetil	367	46.2	46.3
Mycophenolate Mofetil Hydrochloride	367	46.1	46.2
Sirolimus	40	40.2	40.3
Tacrolimus	368	40.1	40.2
Mycophenolic Acid	89	38.8	38.9
Valganciclovir	51	36.9	37.0
Valganciclovir Hydrochloride	51	36.9	37.0
Cyclophosphamide Injection, Solution	289	26.2	26.2
Cyclophosphamide	289	26.2	26.2
Cyclophosphamide For Injection	289	26.2	26.2
Rituximab	329	25.7	25.7
Everolimus Tablets	32	25.7	25.7
Prednisolone	284	25.1	25.2
Prednisolone Oral	284	25.1	25.2
Prednisolone Oral Solution	284	25.1	25.2
Dexamethasone Sodium Phosphate	17	22.3	22.4
Azathioprine	136	22.2	22.2
Etoposide	109	20.9	21.0
Oseltamivir Phosphate	35	19.3	19.3
Cyclosporine	134	17.3	17.3
Fingolimod Hcl	106	17.3	17.3
Thalidomide	46	17.0	17.0
Doxorubicin	105	16.6	16.6
Cytarabine	71	16.3	16.3
Methylprednisolone	152	16.0	16.0
Ganciclovir Sodium	12	15.1	15.1
Bendamustine Hydrochloride	13	14.4	14.5
Human Immunoglobulin G	22	14.3	14.3
Carfilzomib	28	13.3	13.3
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	9	13.3	13.3
Glatiramer Acetate	58	13.3	13.3
Doxorubicin Hydrochloride	32	13.2	13.2
Ganciclovir	10	13.0	13.0
Obinutuzumab	16	13.0	13.0
Daratumumab	37	12.5	12.5
Azacitidine For	17	12.5	12.5
Ifosfamide	20	12.4	12.4
Polatuzumab Vedotin	9	12.2	12.2
Imatinib	16	12.1	12.1
Siponimod	8	11.9	11.9
Ofatumumab	28	11.3	11.3
Daspone	8	10.9	10.9
Dapsone Gel, 5%	8	10.9	10.9
Posaconazole Delayed-Release	9	10.9	10.9
Axicabtagene Ciloleucel	8	10.7	10.8
Dapsone	8	9.9	9.9
Zidovudine	10	9.9	9.9
Anti-Thymocyte Globulin (Rabbit)	6	9.9	9.9
Cladribine	7	9.7	9.7
Vincristine Sulfate	21	9.6	9.6
Mirtazapine	61	9.1	9.1
Teriflunomide	30	8.9	8.9
Azacitidine	19	8.5	8.5
Everolimus	32	8.5	8.5
Belimumab	20	8.4	8.4
Interferon Beta-1B	12	8.3	8.3
Lamivudine	19	8.2	8.2
Sofosbuvir	11	7.4	7.4
Lamivudine Oral	14	7.4	7.4
Posaconazole	9	7.3	7.4
Nevirapine	5	7.3	7.3
Dexamethasone 1.5 Mg	149	7.3	7.3
Dexamethasone	149	7.2	7.2
Bortezomib	44	6.7	6.7
Pomalidomide	50	6.6	6.6
Cisplatin	38	6.6	6.6
Ocrelizumab	30	6.5	6.5
Brentuximab Vedotin	5	6.5	6.5
Bleomycin Sulfate	5	6.4	6.4
Ozanimod Hydrochloride	4	6.4	6.4
Natalizumab	77	5.8	5.8
Dalfampridine	28	5.2	5.2
Ruxolitinib	25	4.7	4.7
Dimethyl Fumarate	38	4.2	4.2
Lenalidomide	81	2.6	2.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.